Circumvention of these inhibitory checkpoints has been achieved in a number of preclinical models using conventional chemotherapy, thus restoring tumor cell sensitivity to TRAIL or agonist moAbs targeting DR4 or DR5 [16,138]. The gene discussed is TNFRSF10A; the disease is neoplasm.